SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 12.5% – Should You Sell?

Posted by Brian Himes on Jul 28th, 2026

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) shares were down 12.5% during trading on Tuesday . The company traded as low as $9.44 and last traded at $9.4840. Approximately 3,293,286 shares were traded during trading, a decline of 61% from the average session volume of 8,454,730 shares. The stock had previously closed at $10.84.

Wall Street Analysts Forecast Growth

SLS has been the subject of several recent analyst reports. Alliance Global Partners restated a “buy” rating on shares of SELLAS Life Sciences Group in a research report on Monday, July 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Friday, July 17th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, SELLAS Life Sciences Group has an average rating of “Hold” and a consensus target price of $10.00.

View Our Latest Stock Analysis on SELLAS Life Sciences Group

SELLAS Life Sciences Group Price Performance

The company has a 50 day simple moving average of $10.43 and a 200-day simple moving average of $6.70. The stock has a market cap of $1.95 billion, a P/E ratio of -43.11 and a beta of 2.42.

SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.01.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Larson Financial Group LLC purchased a new position in shares of SELLAS Life Sciences Group during the fourth quarter worth approximately $26,000. California State Teachers Retirement System boosted its stake in shares of SELLAS Life Sciences Group by 22.4% in the 1st quarter. California State Teachers Retirement System now owns 9,337 shares of the company’s stock valued at $39,000 after purchasing an additional 1,709 shares in the last quarter. Beacon Pointe Advisors LLC bought a new position in shares of SELLAS Life Sciences Group during the 4th quarter valued at $38,000. Concurrent Investment Advisors LLC bought a new position in shares of SELLAS Life Sciences Group during the 4th quarter valued at $38,000. Finally, Money Concepts Capital Corp purchased a new position in SELLAS Life Sciences Group in the 4th quarter worth $40,000. 17.38% of the stock is currently owned by institutional investors.

About SELLAS Life Sciences Group

(Get Free Report)

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.